Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?